Our mouse platform technology doesn’t just generate antibodies. We are able to generate optimal antibodies against difficult epitopes. This sidesteps the problems of low immunogenicity, or high homology, which each can result in inadequate antibody generation. Our aim is to create antibodies that can target antigens that have thus far been undruggable.
Our leadership team combines deep scientific background in neurology, oncology, and immunology with extensive experience in drug development, intellectual property law, and business development. Our advisory board includes distinguished researchers and innovators who have made significant contributions to basic research, drug discovery and innovation throughout the life sciences.